GSK Secures First Global Approval for Chronic Hepatitis B Functional Cure
GSK’s new approval is framed as an important milestone for how investors weigh specialty-product progress against the company’s existing risks and pipeline uncertainty. The approval influences expectations for future performance, with the discussion largely centered on market narratives and forecast context rather than additional operational or quantitative details.